Key result
Chronic sildenafil treatment in the ZSF1 obese rat model of HFpEF attenuated hypertension, decreased LV stiffness, and modestly enhanced effort tolerance.
Why the study?
Although decreased PKG activity was proposed as a therapeutic target in HFpEF, RCTs with PDE5 inhibitors showed neutral results, leaving it unclear whether specific subgroups benefit.
Does chronic sildenafil therapy improve hemodynamics and effort tolerance in a young male rat model of HFpEF with metabolic syndrome?
Comparison
Sildenafil 100 mg·Kg −1 ·d −1 vs placebo vs control
Design
Randomized preclinical animal study
Follow-up
Four weeks
Authors
Loading...
Should not change HFpEF practice; hypothesis-generating for sildenafil in metabolic models, needs human trials.
RCT (n=24)
randomly assigned
Does chronic sildenafil therapy improve hemodynamics and effort tolerance in a young male rat model of HFpEF with metabolic syndrome?
Chronic sildenafil therapy attenuated hypertension, decreased LV stiffness, and modestly enhanced effort tolerance in a rat model of HFpEF with metabolic syndrome, suggesting potential benefit in specific patient subgroups.
Leite et al. (2021) conducted an RCT in Metabolic Syndrome and Heart Failure With Preserved Ejection Fraction (n=24). Sildenafil vs. Placebo was evaluated. Chronic sildenafil treatment in the ZSF1 obese rat model of HFpEF attenuated hypertension, decreased LV stiffness, and modestly enhanced effort tolerance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: